FAQ

We are a specialist fund focused on AI-powered pharma SaaS tech and services. Our partners bring deep operator experience building and scaling pharma-tech and life-science services companies, and we don’t just write checks – we partner operationally and co-build with founders.

EHV invests in B2B SaaS pharma tech and tech-enabled pharma services companies. We look for capital-efficient companies that we can add significant value and exit within a reasonable amount of time.

We typically lead or co-lead late seed or early A start-ups, but remain opportunistic if we can add value elsewhere. We are generally part of the first professional money in the company. We take an active role in syndicating our deals with our investment partners to bring in additional capital and value. We tend to lead or co-lead our financing rounds.

EHV invests in passionate management teams that don’t have all the answers – a team that’s willing to be mentored and advised by experienced entrepreneurs to accelerate the growth of their company. We are focused only on Pharma SaaS and tech-enabled Pharma services with a B2B model.

Yes – a thoughtful pitch deck and financial plan are very helpful. We prefer detailed cash forecasts for the next 18-24 months, with an eye toward capital efficiency, scalable margins, and a clear path to pharma buyer adoption or commercialization. Highlight key inflection points, data infrastructure, and defensibility.

We look for clarity on:
* the pain point in the pharma or life-sciences you are addressing,
* how AI, data, or tech enables a defensible competitive moat,
* market size (≥ $1B TAM preferred, strong growth trajectory),
* capital efficiency and margins (software-oriented businesses or scalable services),
* a credible commercialization or exit pathway, and
* a transparent use of capital plan with clear milestones and runway.
If your deck addresses those items concisely, you will catch our attention!

Assuming the company has everything in order – in electronic format – it takes around 30-60 days. If this is your first time going through a due diligence process, do a search on “VC investment due diligence checklist.” The sooner you start organizing due diligence materials, the better. You will eventually need all of these materials in the future, especially as you get ready for an exit event.

Our decision-making process is a venture capital model in that the managing partners (with feedback from the advisory board and broader network) make the final investment decision. We have an agile process of looking at deals. Once we make a decision to invest, the investment is made directly from our committed funds.

You will get hands-on operational partnership: help with pharma commercialization, customer introductions, pricing architecture, early go-to-market planning, recruiting, interim leadership if needed, and strategic advisor network access. We also provide follow-on capital and leverage our deep relationships in pharma and life-sciences to accelerate adoption, scale your business, and pave a path toward a strong exit.